Utrech University Study Indicates That Rexahn’s Zoraxel™ Could Become New-Class Of Drug For Treating Sexual Dysfunction
May 14, 2009 by admin
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced the results of an animal study that further demonstrates Zoraxel as a potential new-class of therapeutic for the effective treatment of sexual dysfunction.
Comments
Feel free to leave a comment...
and oh, if you want a pic to show with your comment, go get a gravatar!